|
| Press Releases |
|
 |
|
| Friday, March 10, 2023 |
|
|
Eisai Receives the "Basic Achievement Grand Prize" at the 2023 J-Win Diversity Award |
| Eisai Co., Ltd. announced today that it was selected as the winner of the "Basic Achievement Grand Prize" at the "2023 J-Win Diversity Award" held by non-profit organization Japan Women's Innovative Network (NPO J-Win). more info >> |
|
|
エーザイ、2023 J-Win ダイバーシティ・アワード「ベーシックアチーブメント大賞」を受賞 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、このたび、特定非営利活動法人ジャパン・ウィメンズ・イノベイティブ・ネットワーク（NPO 法人 J-Win）が主催する「2023 J-Win ダイバーシティ・アワード」において、「ベーシックアチーブメント大賞」を受賞しましたのでお知らせします。 more info >> |
|
| Thursday, March 9, 2023 |
|
|
Eisai Certified as a 2023 Health and Productivity Management Outstanding |
| Eisai Co., Ltd. announced today that it has been certified as a Health and Productivity Management Outstanding Organization in the large enterprise category (White 500) by Japan's Ministry of Economy, Trade and Industry and the Nippon Kenko Kaigi. more info >> |
|
|
エーザイ、「健康経営優良法人2023 ～ホワイト500～」に認定 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、本日、経済産業省と日本健康会議より「健康経営優良法人（大規模法人部門）2023 ～ホワイト500～」に認定されましたのでお知らせします。 more info >> |
|
| Monday, March 6, 2023 |
|
|
FDA Accepts Eisai's Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBITM (lecanemab-irmb) for the Treatment of Alzheimer's Disease |
| Eisai Co., Ltd. and Biogen Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted Eisai's supplemental Biologics License Application (sBLA) for LEQEMBITM (lecanemab-irmb) 100 mg/mL injection for intravenous use, supporting the conversion of the accelerated approval of LEQEMBI to a traditional approval. more info >> |
|
|
エーザイ、「LEQEMBI」についてアルツハイマー病治療薬としてフル承認に向けた生物製剤承認一部変更申請（sBLA）が米国FDAに受理され、優先審査に指定 |
| more info >> |
|
| Thursday, March 2, 2023 |
|
|
バイオジェン・ジャパンとエーザイの日本における多発性硬化症治療剤の共同販促について |
| バイオジェン・ジャパン株式会社（本社：東京都、代表取締役社長：傳 幸諭、以下 バイオジェン・ジャパン）とエーザイ株式会社（本社：東京都、代表執行役CEO：内藤晴夫、以下エーザイ）は、2018年１月より実施していたバイオジェン・ジャパンの多発性硬化症治療剤「テクフィデラ(R)」（一般名：フマル酸ジメチル）、「タイサブリ(R)」（一般名：ナタリズマブ（遺伝子組換え））、「アボネックス(R)」（一般名：インターフェロンベーター1a（遺伝子組換え））に関する日本における共同販促契約を2023年3月末日をもって終了することをお知らせします。 more info >> |
|
|
Biogen Japan and Eisai Provide Update on Co-Promotion Of Multiple Sclerosis Treatments In Japan |
| Biogen Japan Ltd. and Eisai Co., Ltd. announced today the termination of the co-promotion agreement that has been in place since January 2018 for Biogen Japan's multiple sclerosis (MS) treatments TECFIDERA (dimethyl fumarate), TYSABRI (natalizumab, genetic recombinant) and AVONEX (interferon beta 1a, genetic recombinant) in Japan as of March 31, 2023. more info >> |
|
| Tuesday, February 28, 2023 |
|
|
Biologics License Application for Lecanemab Designated for Priority Review by China National Medical Products Administration |
| Eisai Co., Ltd. and Biogen Inc. announced today that the Biologics License Application (BLA) for lecanemab, an investigational anti-amyloid beta (Abeta) protofibril antibody, has been designated for Priority Review by the National Medical Products Administration (NMPA) in China. more info >> |
|
| Friday, May 27, 2022 |
|
|
Eisai: MHLW Grants Orphan Drug Designation in Japan to Mecobalamin Ultrahigh-Dose Formulation with Prospective Indication for Delaying the Progression of Disease and Functional Impairment of ALS |
| Eisai Co., Ltd. announced today that it has received orphan drug designation for ultrahigh-dose mecobalamin, with a prospective indication for delaying the progression of disease and functional impairment of amyotrophic lateral sclerosis (ALS), by the Ministry of Health, Labour and Welfare (MHLW). more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
康哲藥業（867.HK/8A8.SG）：磷酸蘆可替尼乳膏獲批 為中國批准的首款且唯一白癜風靶向藥
Feb 2, 2026 14:49 HKT/SGT
|
|
|
Muyuan Foods IPO: Hog Giant's Profit Growth Outpaces Top 10 Global Meat Firms, Eyes Global Expansion
Feb 2, 2026 14:17: JST
|
|
|
COSMOPlat, Serving 160,000 Firms, Files for Hong Kong IPO on "AI+Industrial Internet" Wave
Feb 2, 2026 13:29 HKT/SGT
|
|
|
Muyuan Foods IPO: Hog Giant's Profit Growth Outpaces Top 10 Global Meat Firms, Eyes Global Expansion
Feb 2, 2026 13:17 HKT/SGT
|
|
|
富士通、ＳＭＢＣ日興証券様のオンライン取引の不正アクセス対策として、生体認証サービスを導入
Feb 2, 2026 12:30: JST
|
|
|
JCB Launches Usage Promotion Campaign for Inbound Visitors in Fukuoka's Tenjin Area
Feb 2, 2026 10:00 JST
|
|
|
Web-based tool makes it easier to design advanced materials
Feb 2, 2026 08:00 HKT/SGT
|
|
|
TCG.Zone Announces Strategic Pivot to High-Value Collectible Assets
Feb 1, 2026 18:00: JST
|
|
|
TCG.Zone Announces Strategic Pivot to High-Value Collectible Assets
Feb 1, 2026 17:00 HKT/SGT
|
|
|
Five Global Megatrends Highlighted at Open Dialogue Expert Forum at the Russia National Centre
Jan 31, 2026 21:00 HKT/SGT
|
|
|
Five Global Megatrends Highlighted at Open Dialogue Expert Forum at the Russia National Centre
Jan 31, 2026 21:00: JST
|
|
|
日清食品（香港）慈善基金连续第四年支持 香港教育大学精英运动员
Jan 31, 2026 07:21 HKT/SGT
|
|
|
REMSleep Receives Medicare PDAC Coding Approval for Complete DeltaWave Product Portfolio
Jan 31, 2026 02:40 HKT/SGT
|
|
|
CMS (867.HK/8A8.SG): Ruxolitinib Phosphate Cream Obtained China NDA Approval, Becoming The First and Only Targeted Drug for Vitiligo in China
Jan 30, 2026 22:30: JST
|
|
|
NTT DOCOMO Concludes Partnership Agreement with Aduna to Advance Global Network API Expansion
Jan 30, 2026 22:50 JST
|
|
|
|
|
More News >> |
|
|
|
|
|
